Welcome to our dedicated page for fldm news (Ticker: fldm), a resource for investors and traders seeking the latest updates and insights on fldm stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect fldm's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of fldm's position in the market.
Fluidigm Corporation (NASDAQ: FLDM) announced preliminary revenue for Q4 and full year 2021, surpassing expectations. Q4 revenue is projected between $38.0 and $38.3 million, exceeding guidance of $31–$34 million. Full year revenue is estimated at $130.3 to $130.6 million, above the prior range of $123–$127 million. The strong growth includes approximately 13% for Q4 and 12% for the full year, driven by new products like Biomark OEM and CyTOF XT. Final results will be reported in February 2022.
Fluidigm Corporation (NASDAQ:FLDM) has announced that its Advanta Dx SARS-CoV-2 RT-PCR Assay effectively detects the COVID-19 virus, including the Omicron variant, based on in silico analyses. The assay, designed for non-invasive saliva testing, has shown 100% agreement with traditional nasopharyngeal swabs. Since August 2020, millions of samples have been tested, highlighting the assay's accessibility and accuracy. Fluidigm continues to monitor viral mutations to ensure the assay's effectiveness in public health initiatives.
Fluidigm Corporation (Nasdaq:FLDM) announces participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. CEO Chris Linthwaite and CFO Vikram Jog will provide updates on the company's business strategy and financial performance. A pre-recorded fireside chat will be available on demand on November 22, 2021, at 10:00 a.m. ET, followed by virtual one-on-one meetings on November 30, 2021. The webcast of the chat will be archived for 90 days on Fluidigm's investor website, emphasizing its commitment to advancing health insights through innovative research solutions.
Fluidigm Corporation (NASDAQ: FLDM) announced the launch of its Biomark™ X microfluidics platform aimed at enhancing genomics research. The Biomark X integrates existing platforms, simplifying workflows, reducing hands-on time, and accelerating results. CEO Chris Linthwaite emphasized its potential to lower labor costs and improve research capabilities across various sectors, including pharmaceutical and clinical labs. The phased launch is set to begin in Q1 2022, aligning with Fluidigm's Vision 2025 innovation objectives.
Fluidigm Corporation (Nasdaq: FLDM) announced its Q3 2021 financial results, reporting total revenue of $28.5 million, a decline from $39.9 million in Q3 2020. The GAAP net loss widened to $13.8 million, compared to a loss of $6.0 million a year ago. Supply chain challenges led to a backlog of over $9 million in unfilled orders and affected guidance for 2021 revenue, now expected to be between $123 million and $127 million. Strategic reviews to enhance shareholder value are in progress. The company highlighted innovations in mass cytometry and microfluidics and ongoing clinical trials using its technology.
Fluidigm Corporation (NASDAQ: FLDM) has announced its Imaging Mass Cytometry™ (IMC™) technology will be utilized in studies by Weill Cornell Medicine aimed at uncovering molecular links between African ancestry and aggressive cancers. Funded by the New York Genome Center’s Polyethnic-1000 initiative, the research also addresses racial disparities in cancer outcomes. The Polyethnic-1000 program seeks to enhance understanding of ethnic contributions to cancer incidence. Fluidigm's Hyperion™ Imaging System is integral to these studies, promising advancements in cancer prevention and treatment.
Fluidigm Corporation (Nasdaq:FLDM) will report its third quarter 2021 financial results on November 8, 2021, after market close. CEO Chris Linthwaite and CFO Vikram Jog will host a conference call at 1:30 p.m. PT to discuss the results and operational progress. Interested parties can listen by calling designated numbers or through a live webcast on the company's Investor Relations page. The webcast will be archived for later access. Fluidigm specializes in biotechnology tools, focusing on translational and clinical research applications.
Fluidigm Corporation (NASDAQ:FLDM) announced the agenda for its upcoming IMC Summit on October 21, 2021, focusing on Imaging Mass Cytometry (IMC) and its application in various research areas including immunology and infectious diseases. The summit highlights recent advancements in IMC, featuring presentations from renowned scientists and the introduction of Maxpar OnDemand Antibodies, which significantly expands antibody options for IMC. The event aims to foster collaboration within the scientific community, notably addressing pressing health issues, including insights related to COVID-19 and breast cancer.
Fluidigm Corporation (NASDAQ: FLDM) announced a new co-marketing program with Visiopharm to enhance data analysis through the Hyperion Imaging System. This collaboration enables the native reading of Imaging Mass Cytometry data files using Visiopharm's software, improving workflow efficiency for researchers. The new software will launch at the Fluidigm IMC Summit on October 21, 2021. With mass cytometry being employed by major pharmaceutical companies and utilized in numerous clinical trials, this partnership aims to simplify and accelerate data analysis in translational and clinical research.
Fluidigm Corporation (NASDAQ: FLDM) has announced a collaboration with Karolinska Institutet to enhance research applications and product development using the CyTOF XT system. This partnership focuses on immunological studies in the Department of Women’s and Children’s Health, aiming to unlock new insights into immune system behavior, especially regarding early childhood development. The CyTOF XT platform, launched in 2021, is poised to improve therapeutic research outcomes, featuring advancements in throughput and automation. This collaboration is a strategic move to strengthen Fluidigm's position in translational and clinical research.
FAQ
What is the market cap of fldm (fldm)?
